Germany's Stada Strengthens Central, Eastern European Focus With Brand, Generic Buys
This article was originally published in The Pink Sheet Daily
Stada spends $537 million on Grünenthal's branded product portfolio in Central and Eastern Europe and Spirig's generics business in Switzerland.
You may also be interested in...
Grunenthal CEO Claims German Reimbursement Hurdle Is Fair, As Pain Drug Palexia Rolls Out Across Europe
German reimbursement authority’s strong emphasis on drugs’ added benefit is logical, opines Grunenthal CEO Harald Stock. And all health care systems will eventually move the same way.
Europe's tough pricing and reimbursement environment may make it a graveyard for growth in innovative drugs, but there's still plenty of upside in generics, particularly of the branded, specialist kind.
Family-owned Grünenthal GMBH has opened up to the outside world, significantly stepping up deal-making as it aims for "global innovation leadership" in pain management.